This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Chabner E, Schnitt S, Harris J. Current management of patients with ductal carcinoma in situ. Oncologist. 1997;2(2):76–82.
Sagara Y, Mallory MA, Wong S, et al. Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study. JAMA Surg. 2015;150(8):739–45.
Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC Cancer Staging Manual: breast cancer. Ann Surg Oncol. 2018;25(7):1783–5.
Rakovitch E, Nofech-Mozes S, Hanna W, et al. A population-based validation study of the DCIS score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015;152(2):389–98.
Manders JB, Kuerer HM, Smith BD, et al. Clinical utility of the 12-gene DCIS score assay: impact on radiotherapy recommendations for patients with ductal carcinoma in situ. Ann Surg Oncol. 2017;24(3).660–8.
Piltin MA, Hoskin TL, Day CN, Shumway DA, Habermann EB, Davis J, Boughey JC. Use of the twelve-gene recurrence score for ductal carcinoma in situ and its influence on receipt of adjuvant radiation and hormonal therapy. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-020-09517-z.
The authors have no conflicts of interest or sources of funding to disclose.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Piltin, M.A., Boughey, J.C. ASO Author’s Reflections: Are Genomic Assays Informing the Management of Ductal Carcinoma in situ as They Have for Invasive Breast Cancer?. Ann Surg Oncol (2021). https://doi.org/10.1245/s10434-020-09573-5